|Bid||45.50 x 900|
|Ask||45.82 x 2900|
|Day's Range||45.21 - 45.67|
|52 Week Range||33.53 - 45.67|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||19.79|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||2.20 (5.08%)|
|Ex-Dividend Date||Nov 18, 2021|
|1y Target Est||46.27|
The pharmaceutical giant GlaxoSmithKline said Saturday it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit, a joint venture it controls in a partnership with Pfizer.
(Bloomberg) -- Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, according to people familiar with the matter. Most Read from BloombergDjokovic Loses Shot at Tennis History as Australia Deports StarOne of the World’s Wealthiest Oil Exporters Is Becoming UnlivablePutin’s Troops Wouldn’t Get Cheers in This Once Pro-Russia CityDirecTV to Drop One America News in Blow to Conservative ChannelShould I
Unilever will be forced to raise £14bn from investors or sell assets to fund any sweetened offer for GlaxoSmithKline’s consumer healthcare business as the City cast doubt on the Marmite maker’s surprise bid.